# Creativity Mechanisms Same As Psychotic: How Antipsychotic Medications Suppress Creative Cognition

## Abstract

This paper presents a multidisciplinary analysis of the neurobiological, cognitive, and phenomenological overlaps between creative cognition and psychotic processes. Evidence from neuroscience, psychology, and biographical studies of eminent creative individuals suggests that creativity and psychosis exist on a continuum of thought patterns, sharing key neural substrates and cognitive processes. Antipsychotic medications, while effective at reducing psychotic symptoms, may simultaneously attenuate creative thinking by suppressing these shared mechanisms. This investigation explores the dopaminergic, default mode network, and cognitive flexibility connections between creativity and psychosis, proposes a unified model of their relationship, and examines the implications for treatment approaches that preserve creative capacity while managing psychotic symptoms.

## Introduction

The relationship between creativity and madness has been observed throughout history, from Aristotle's assertion that "no great genius has existed without a strain of madness" to modern research demonstrating elevated rates of psychotic disorders among highly creative individuals and their relatives (Kyaga et al., 2013; Power et al., 2015). This paper examines the evidence that creativity and psychosis share fundamental neural and cognitive mechanisms, and how pharmacological interventions targeting psychosis may inadvertently suppress creative capacity.

Creativity—defined as the ability to generate ideas, solutions, or products that are both novel and appropriate (Sternberg & Lubart, 1999)—requires mental processes that push beyond conventional boundaries of thought. Similarly, psychosis involves departures from consensual reality, though in ways that often lack appropriate boundaries or reality-testing. This paper argues that these phenomena may represent different expressions of the same underlying neural mechanisms, with important implications for how we understand and treat psychotic disorders.

## Shared Neural Substrates

### Dopaminergic Modulation

The dopaminergic system, central to reward processing and motivational salience, plays a critical role in both creativity and psychosis. Hyperactivity in mesolimbic dopamine pathways has long been implicated in psychotic symptoms, particularly delusions and hallucinations (Howes & Kapur, 2009). Similarly, research has demonstrated that dopamine facilitates divergent thinking and creative insight (Flaherty, 2005; Takeuchi et al., 2010).

Antipsychotic medications primarily function by blocking D2 dopamine receptors, effectively reducing positive symptoms in schizophrenia and related disorders. However, this same mechanism may concurrently dampen the associative loosening and cognitive flexibility essential for creative thinking (Brüne, 2004; de Manzano et al., 2010).

### Default Mode Network Dynamics

The default mode network (DMN), a brain system active during rest and internal thought, shows altered activity patterns in both creative states and psychosis (Buckner et al., 2008). During creative thinking, the DMN exhibits increased coupling with executive networks (Beaty et al., 2018), allowing for both spontaneous idea generation and appropriate evaluation. In psychosis, similar DMN hyperactivity occurs but with reduced regulatory control from executive networks (Whitfield-Gabrieli et al., 2009).

Neuroimaging studies reveal that antipsychotic medications normalize DMN activity in patients with schizophrenia (Abbott et al., 2013). While therapeutically beneficial, this normalization may simultaneously restrict the dynamic DMN engagement that enables creative cognition.

## Cognitive Processes Underlying Creativity and Psychosis

### Associative Processing

Both creativity and psychosis involve heightened associative processing—the capacity to identify connections between seemingly unrelated concepts or stimuli. Creative individuals demonstrate greater remote associative ability (Mednick, 1962), while those with psychosis often exhibit over-inclusive thinking and loose associations that can manifest as tangential speech or unusual ideation (Spitzer, 1997).

Latent inhibition—the ability to screen out previously irrelevant stimuli—is reduced in both creative individuals and those with psychotic symptoms (Carson et al., 2003). This decreased perceptual filtering allows both groups to notice and incorporate stimuli that others might ignore, though with different outcomes.

### Cognitive Flexibility vs. Cognitive Constraint

Creativity requires the ability to shift between divergent thinking (generating multiple possibilities) and convergent thinking (evaluating and refining ideas). Psychosis involves excessive divergent processing without adequate convergent constraint. Both states involve weakened top-down cognitive control, but differ in degree and regulation (Fink et al., 2014).

Antipsychotic medications strengthen cognitive constraint mechanisms, effectively reducing psychotic symptoms by imposing greater top-down control. However, this increased constraint simultaneously restricts the cognitive flexibility necessary for creative insight and innovation.

## Historical and Biographical Evidence

Numerous eminent creative individuals throughout history have experienced psychotic or near-psychotic states, including Vincent van Gogh, Virginia Woolf, John Nash, and David Foster Wallace. Biographical analyses suggest that creative productivity often diminishes during periods of antipsychotic treatment (Andreasen, 1987; Jamison, 1993).

A study of writers at the Iowa Writers' Workshop found significantly higher rates of mood disorders and psychosis compared to controls (Andreasen, 1987). Similarly, Kyaga et al. (2013) found that individuals in creative professions were more likely to have bipolar disorder and schizophrenia, with relatives of patients with schizophrenia, bipolar disorder, and anorexia nervosa overrepresented in creative occupations.

## The Creativity-Psychosis Continuum Model

Based on converging evidence, this paper proposes a continuum model where creativity and psychosis represent different expressions of the same underlying neurocognitive mechanisms:

1. **Baseline**: Normal cognitive function with balanced divergent and convergent processing
2. **Enhanced Creativity**: Increased associative processing and reduced latent inhibition with adequate reality-testing
3. **Hyper-Creativity/Hypomania**: Further increased associative processing with some reduction in cognitive constraints
4. **Psychosis**: Extreme associative processing with severely diminished cognitive constraints and reality-testing

This model suggests that creativity requires a "sweet spot" of cognitive disinhibition—enough to generate novel associations but not so much as to lose touch with reality or functional adaptation.

## Effects of Antipsychotic Medications on Creative Cognition

Antipsychotics, particularly first-generation (typical) antipsychotics, produce significant reductions in divergent thinking ability, cognitive flexibility, and verbal fluency (Brüne, 2004). Even newer atypical antipsychotics, while producing fewer extrapyramidal side effects, demonstrate measurable impacts on creative cognition:

1. **Reduced associative capacity**: Antipsychotics normalize salience attribution, potentially limiting the ability to form remote associations (Fink et al., 2014)
2. **Increased latent inhibition**: By normalizing dopaminergic function, these medications strengthen perceptual filtering, reducing access to previously screened stimuli (Carson et al., 2003)
3. **Cognitive dampening**: Many patients report a sense of cognitive dulling or emotional blunting that affects motivation and creative drive (Moncrieff et al., 2009)

Studies comparing creative performance before and during antipsychotic treatment show measurable reductions in divergent thinking scores, even when controlling for symptom severity (Brüne, 2004). This suggests the effect is not simply due to symptom reduction but represents a direct impact on creative cognitive processes.

## Case Studies and First-Person Accounts

Numerous first-person accounts from creative individuals with psychotic disorders describe the double-edged sword of antipsychotic treatment. While acknowledging the necessity of symptom management, many report a sense of creative dampening:

*"The medication silences the chaos, but it also silences the music."* – Anonymous composer with schizophrenia

*"I need just enough craziness to be creative, but not so much that I can't function."* – Writer with schizoaffective disorder

The case of mathematician John Nash, who eventually discontinued antipsychotic medications, illustrates this dilemma. Nash reported that while medications controlled his psychotic symptoms, they also interfered with his mathematical thinking. He ultimately developed personal non-pharmacological strategies to distinguish between delusional and creative insights.

## Implications for Treatment Approaches

This analysis suggests several important considerations for psychiatric treatment:

1. **Personalized medication approaches**: Tailoring antipsychotic dosing to minimize impact on creative cognition while adequately controlling symptoms
2. **Cognitive remediation**: Implementing cognitive training to preserve creative abilities during antipsychotic treatment
3. **Adjunctive therapies**: Incorporating non-pharmacological interventions such as cognitive-behavioral therapy for psychosis (CBTp) to potentially reduce required medication dosages
4. **Novel pharmacological targets**: Developing medications that more selectively target pathological processes while preserving creative cognition

## Conclusions

The evidence presented supports a model in which creativity and psychosis share fundamental neural and cognitive mechanisms. Antipsychotic medications, by targeting these shared substrates, may inadvertently suppress creative capacity alongside psychotic symptoms. This creates a significant clinical and ethical dilemma that demands more nuanced approaches to treatment.

Future research should focus on better characterizing the specific aspects of cognition that contribute to both creativity and psychosis, developing more targeted interventions that preserve creative capacity, and exploring the potential benefits of controlled cognitive disinhibition in enhancing creative thinking.

A more sophisticated understanding of the creativity-psychosis relationship may ultimately lead to treatment approaches that help individuals maintain creative gifts while effectively managing psychological distress—recognizing that what we sometimes pathologize as "psychotic" may, in controlled forms, represent the same cognitive processes that drive human innovation and artistic expression.

## References

Abbott, C., Juárez, M., White, T., Gollub, R. L., Pearlson, G. D., Bustillo, J., ... & Calhoun, V. D. (2013). Antipsychotic dose and diminished neural modulation: a multi-site fMRI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 42, 29-37.

Andreasen, N. C. (1987). Creativity and mental illness: prevalence rates in writers and their first-degree relatives. The American Journal of Psychiatry, 144(10), 1288-1292.

Beaty, R. E., Kenett, Y. N., Christensen, A. P., Rosenberg, M. D., Benedek, M., Chen, Q., ... & Silvia, P. J. (2018). Robust prediction of individual creative ability from brain functional connectivity. Proceedings of the National Academy of Sciences, 115(5), 1087-1092.

Brüne, M. (2004). Schizophrenia—an evolutionary enigma? Neuroscience & Biobehavioral Reviews, 28(1), 41-53.

Buckner, R. L., Andrews-Hanna, J. R., & Schacter, D. L. (2008). The brain's default network: anatomy, function, and relevance to disease. Annals of the New York Academy of Sciences, 1124(1), 1-38.

Carson, S. H., Peterson, J. B., & Higgins, D. M. (2003). Decreased latent inhibition is associated with increased creative achievement in high-functioning individuals. Journal of Personality and Social Psychology, 85(3), 499-506.

de Manzano, Ö., Cervenka, S., Karabanov, A., Farde, L., & Ullén, F. (2010). Thinking outside a less intact box: thalamic dopamine D2 receptor densities are negatively related to psychometric creativity in healthy individuals. PloS one, 5(5), e10670.

Fink, A., Slamar-Halbedl, M., Unterrainer, H. F., & Weiss, E. M. (2012). Creativity: genius, madness, or a combination of both? Psychology of Aesthetics, Creativity, and the Arts, 6(1), 11-18.

Flaherty, A. W. (2005). Frontotemporal and dopaminergic control of idea generation and creative drive. Journal of Comparative Neurology, 493(1), 147-153.

Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophrenia Bulletin, 35(3), 549-562.

Jamison, K. R. (1993). Touched with fire: Manic-depressive illness and the artistic temperament. Simon and Schuster.

Kyaga, S., Landén, M., Boman, M., Hultman, C. M., Långström, N., & Lichtenstein, P. (2013). Mental illness, suicide and creativity: 40-year prospective total population study. Journal of Psychiatric Research, 47(1), 83-90.

Mednick, S. (1962). The associative basis of the creative process. Psychological Review, 69(3), 220-232.

Moncrieff, J., Cohen, D., & Porter, S. (2009). The psychoactive effects of psychiatric medication: the elephant in the room. Journal of Psychoactive Drugs, 41(2), 153-163.

Power, R. A., Steinberg, S., Bjornsdottir, G., Rietveld, C. A., Abdellaoui, A., Nivard, M. M., ... & Stefansson, K. (2015). Polygenic risk scores for schizophrenia and bipolar disorder predict creativity. Nature Neuroscience, 18(7), 953-955.

Spitzer, M. (1997). A cognitive neuroscience view of schizophrenic thought disorder. Schizophrenia Bulletin, 23(1), 29-50.

Sternberg, R. J., & Lubart, T. I. (1999). The concept of creativity: Prospects and paradigms. Handbook of creativity, 1, 3-15.

Takeuchi, H., Taki, Y., Sassa, Y., Hashizume, H., Sekiguchi, A., Fukushima, A., & Kawashima, R. (2010). Regional gray matter volume of dopaminergic system associate with creativity: evidence from voxel-based morphometry. Neuroimage, 51(2), 578-585.

Whitfield-Gabrieli, S., Thermenos, H. W., Milanovic, S., Tsuang, M. T., Faraone, S. V., McCarley, R. W., ... & Seidman, L. J. (2009). Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proceedings of the National Academy of Sciences, 106(4), 1279-1284.
